Other Medicines
Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 1-7 out of 7 results
Other Medicines
Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study
Other Medicines
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1
Other Medicines
Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis
Other Medicines
Donidalorsen Data Presented at the American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress
Other Medicines
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
Other Medicines
Inhibition of Prekallikrein for Hereditary Angioedema